Demant A/s Stock Earnings Reports

Demant reported full-year 2025 results with modest overall growth and margin pressure. Key financials: 2% organic growth (5% in local currencies, 2% reported), gross profit up modestly but gross margin compressed by ASP and product/geography mix, EBIT before special items declined ~10% in H2 and ended at DKK 3.96bn for the year, free cash flow remained strong (~DKK 3bn+ for the year). Major corporate actions: acquisition of KIND (closed Dec 2025) to strengthen Hearing Care (now the largest business area); announced divestments of EPOS and Oticon Medical to focus on hearing healthcare. Product momentum: Oticon Zeal launched in selected markets in 2025 with strong initial uptake and is expected to be a primary driver of market-share gains in 2026 as rollout continues (U.S., Canada, France and broader rollouts planned). Margin drivers and headwinds: ASP pressure from channel/geography mix (notably U.K. NHS, France and lower‑priced channels) and weaker U.S. hearing-aid market; Diagnostics had a stronger Q4 but faced some tariff-related margin impact. Capital allocation and balance sheet: KIND acquisition drove net debt and leverage to ~3.4x (above the 2–2.5x target); share buyback paused for 2026 to prioritize deleveraging with a stated plan to return to the target gearing within 18–24 months. Cost actions: a company-wide profitability program expected to deliver ~DKK 250m EBIT benefit in 2026 (with ~DKK 500m structural savings from 2028), including one-off restructuring costs of DKK 200m in 2026 (plus DKK 100m in 2027) and affect ~700 roles globally. 2026 outlook: organic growth guidance 3–6%, EBIT before special items DKK 4.1–4.5bn, acquisitive growth assumed ~8%, FX drag (~-2%) and special items ~-DKK 325m. Sustainability: progress on scope 1+2 emissions (16% reduction vs baseline), improved lives reached (~12m), and gender diversity at 33% in top management.